Anika Therapeutics grants 2,500 non-statutory stock options at $9.15.
ByAinvest
Friday, Sep 5, 2025 5:04 am ET1min read
ANIK--
The stock options vest over three years, with one-third vesting annually. The options will expire after ten years and are subject to the terms and conditions outlined in the equity award agreement approved by Anika. The grant was made in compliance with Nasdaq Listing Rule 5635(c)(4), which requires companies to disclose material inducements to employment as part of their compensation packages.
Anika Therapeutics, Inc. is committed to delivering and advancing osteoarthritis pain management and orthopedic regenerative solutions. The company's global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.
References:
[1] https://www.marketscreener.com/news/anika-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ce7d59d9d889f42d
[2] https://www.globenewswire.com/news-release/2025/09/05/3145141/28467/en/Anika-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
[3] https://www.stocktitan.net/news/ANIK/anika-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-1f04vu2xj6eu.html
Anika Therapeutics granted non-statutory stock options covering 2,500 shares of common stock to a newly hired non-executive employee at a per share exercise price of $9.15. The grant was made under the Anika Therapeutics, Inc. 2021 Inducement Plan and was approved by the compensation committee of the board of directors. The grant was a material inducement to the employee's acceptance of employment.
Anika Therapeutics, Inc. (NASDAQ: ANIK), a leading player in osteoarthritis pain management and regenerative solutions, has granted non-statutory stock options to a newly hired non-executive employee. The grant, made on September 2, 2025, covers 2,500 shares of common stock at a per share exercise price of $9.15. The grant was executed under the Anika Therapeutics, Inc. 2021 Inducement Plan and was approved by the compensation committee of the board of directors. This move was a material inducement to the employee's acceptance of employment with Anika.The stock options vest over three years, with one-third vesting annually. The options will expire after ten years and are subject to the terms and conditions outlined in the equity award agreement approved by Anika. The grant was made in compliance with Nasdaq Listing Rule 5635(c)(4), which requires companies to disclose material inducements to employment as part of their compensation packages.
Anika Therapeutics, Inc. is committed to delivering and advancing osteoarthritis pain management and orthopedic regenerative solutions. The company's global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.
References:
[1] https://www.marketscreener.com/news/anika-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ce7d59d9d889f42d
[2] https://www.globenewswire.com/news-release/2025/09/05/3145141/28467/en/Anika-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
[3] https://www.stocktitan.net/news/ANIK/anika-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-1f04vu2xj6eu.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet